Alnylam

  www.alnylam.com
Work in HR? Unlock Free Profile

Alnylam Reviews

Updated May 17, 2014

Be The First To
Add Photos

All Employees Current Employees Only

3.5 6 reviews

80% Approve of the CEO

Alnylam CEO and Director John M. Maraganore

John M. Maraganore

(5 ratings)

50% of employees recommend this company to a friend
3 Employee Reviews Back to all reviews
Relevance Date Rating
in
    • Culture & Values
    • Work/Life Balance
    • Senior Management
    • Comp & Benefits
    • Career Opportunities
    • Approves of CEO

     

    Good place to work

    Consultant Scientist (Current Employee) Cambridge, MA

    ProsEmployees are treated well. Very well compensated and flexible hours. Never micromanaged!

    ConsNothing I can think off!

    Advice to Senior ManagementKeep up the good work! I wish to join this company again!

    Yes, I would recommend this company to a friend

    • Culture & Values
    • Work/Life Balance
    • Senior Management
    • Comp & Benefits
    • Career Opportunities
    • Approves of CEO

    1 person found this helpful  

    Loved the people!

    Research Associate (Former Employee) Cambridge, MA

    ProsI absolutely loved my group! The culture there was awesome!
    My group was like my second family. I will miss them.

    ConsWe went through two restructurings with no warning...need I say more?

    Advice to Senior ManagementShare with the employees more of what is going on with the big picture.

    – I'm not optimistic about the outlook for this company

    • Work/Life Balance
    • Senior Management
    • Comp & Benefits
    • Career Opportunities
    • Approves of CEO

    1 person found this helpful  

    Dynamic fast-paced environment, aggressively prosecuting a novel therapeutic technology

    Anonymous Employee (Current Employee) Cambridge, MA

    ProsStrong scientific rigor, very dynamic environment, compelling new technology, good fiscal management, heavily matrixed organization that demands good team play and collaboration

    ConsALNY is aggressively seeking clinical POC for the RNAi therapeutic platform. The intense race toward clinical results often means that research around better understanding the fundamentals of the technology are deprioritized. Target selection also feels rushed and premature at times.

    Advice to Senior ManagementDon't overlook mechanistic research around targets and delivery systems as this provides a strong foundation for problem solving later in clinical development.

Worked for Alnylam? Contribute to the Community!

Your response will be removed from the review – this cannot be undone.